Stay updated on Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page
- CheckyesterdayChange DetectedA new revision label, v3.5.4, was added to the study documents and the previous label v3.5.3 was removed, indicating an updated documentation version in the record. This reflects an update to the study's protocol/documentation in the ClinicalTrials.gov record.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThis change updates the site/revision version shown in the page footer from v3.5.2 to v3.5.3, indicating a minor release of the ClinicalTrials.gov page display.SummaryDifference0.1%

- Check29 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. This update appears to be an internal version change to the page.SummaryDifference0.1%

- Check65 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check93 days agoChange DetectedA new site Revision: v3.4.2 appears, and the previous government funding notice (and Revision: v3.4.1) has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.